A Phase 1 Open-Label Multicenter Dose-Escalation Dose- Expansion and Dose-Randomization Study of IO-108 as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors.

Go Back to All Clinical Trials

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Other Inclusion Criteria:

1. Patient must have any histologically or cytologically confirmed advanced or metastatic solid tumor and has received, has been intolerant to, or has been ineligible for standard systemic therapy known to confer clinical benefit. 2. Solid tumors of any type are eligible for enrollment. 3. Patient has progressed or relapsed after at least 6 weeks of PD-1/PD-L1 inhibitor therapy. 4. Patient must have measurable disease per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) as assessed by local clinical site.

1. Patient who previously received leukocyte immunoglobulin-like receptor subfamily B (LILRB) immunoglobulin-like transcript (ILT) targeting agents, including those targeting LILRB1 (ILT2), LILRB2 (ILT4), or leukocyte associated immunoglobulin-like receptor 1 (LAIR1). 2. Patient who received a biologic systemic anti-cancer therapy <3 weeks or 5 half-lives, whichever is shorter, prior to their first day of study drug administration, or a small molecule systemic anti-cancer therapy or definitive radiotherapy <2 weeks or 5 half-lives prior to their first day of study drug administration or who has not recovered to NCI CTCAE v5.0 Grade 1 or better from any AE that was due to prior cancer therapeutics. Palliative radiation is allowed within 2 weeks of the first day of study drug administration. 3. Patient requires systemic corticosteroids at a dose of >10 mg prednisone or the dose equivalent to another systemic corticosteroid. 4. Patient has a history of radiation pneumonitis, non-infectious pneumonitis, or interstitial lung disease. 5. Patient has symptomatic CNS spread of tumor.